TUCSON, Ariz., July 23, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced Vinodh Pillai, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at the Children’s Hospital of Philadelphia, and Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, as award recipients of its 2020 HTG EdgeSeq Autoimmune Panel Research Grants.
Problem: SARS-CoV-2 is a novel coronavirus that causes different degrees of morbidity and mortality host response
Following End of Qiagen Deal, HTG Molecular to Focus on CDx Plans and Other Alliances
The digital edition of the HTG EdgeSeq System User Manual (RUO) is a new tool designed to stream-line and enhance your customer experience.
HTG and Firalis are nominated for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcome by the Galien Foundation Medstartup 2018.
The Worldwide Innovative Networking (WIN) Consortium at its annual symposium this week provided an update on its precision oncology clinical trial pipeline.
Interview with TJ Johnson, CEO of HTG Molecular, on the development of new oncology offerings with pharmaceutical companies and how QIAGEN and HTG have partnered to provide an entire workflow from biomarker discovery to companion diagnostic development.
"The HTG EdgeSeq technology represents a nice way to combine the possibility of working with FFPE specimens and next-generation approaches. Moreover, the HTG EdgeSeq Oncology Biomarker Panel (OBP) can be applied on in vitro models and then the results can be validated on FFPE specimens from clinical studies using the same assay." Dr. Bertoni, MD
A QIAGEN interview with John Lubniewski at the 2017 ASCO Conference on the importance of Immuno-Oncology
Page last updated October 21, 2022